Survivin and angiotensin-converting enzyme polymorphisms with risk of colorectal cancer: a systematic review and meta-analysis
© Zhou and Lin; licensee BioMed Central. 2015
Received: 23 September 2014
Accepted: 10 January 2015
Published: 7 February 2015
Colorectal cancer (CRC) is the most common cause of cancer death worldwide. Numerous studies have identified the roles of survivin −31 G/C and angiotensin-converting enzyme insertion/deletion (ACE I/D) polymorphisms in CRC risk; however, the results remain inconclusive. This study was to investigate associations between these two polymorphisms and CRC susceptibility.
A comprehensive literature search was conducted to collect relevant case–control studies published between 2000 and 2014. The extracted data were statistically analyzed, and the odds ratios (ORs) with 95% confidence intervals (CIs) were employed to estimate the strength of association.
A total of 11 studies were included in the meta-analysis. For survivin G/C polymorphism, six articles reported 1,840 cases and 1,804 controls. Overall, we found the frequency of C allele is higher in CRC cases than that in the healthy controls (57.2% vs. 48.0%), and C allele significantly increased the risk of CRC compared to G allele in allele model (OR = 1.46, 95% CI = 1.33–1.60, P < 0.00001). This association was also found in other genetic models (P < 0.00001). Stratified analysis by ethnicity showed significant association in each genetic model among the Asian population. For ACE I/D polymorphism, five studies included 758 cases and 6,755 controls. No significant association was found in any genetic models.
Our results showed that survivin −31 G/C polymorphism might contribute to risk of CRC, especially in the Asian populations. However, the ACE I/D polymorphism is not a genetic factor concerning the risk for CRC. More studies with larger sample sizes are required in the future.
KeywordsColorectal cancer Survivin Angiotensin-converting enzyme Polymorphism Meta-analysis
Colorectal cancer (CRC) is one of the three most common cancers in the world and is a major contributor to cancer-related death . Each year, a global incidence exceeding 1.2 million new cases emerge and 600,000 deaths occur . Its incidence rates continue to increase in economically transitioning countries. According to colorectal cancer statistics, an estimated 71,830 men and 65,000 women will be diagnosed with CRC, and 26,270 men and 24,040 women will die of this disease in 2014 . The etiological factors and pathogenetic mechanisms underlying CRC development appear to be complex and heterogeneous. In the last two decades, studies have demonstrated that CRC cells undergo major epigenetic alterations . Among which, genetic variants in oncogenes have been extensively investigated as the essential role in cancer etiology .
The survivin gene, located in chromosome 17q25, is the smallest member of the inhibitor of apoptosis (IAP) gene family . It is a multifunctional protein and is required to preserve tissue or organism viability . Survivin is expressed in many human cancers and involved in the regulation of cell division and survival . The survivin −31 G/C polymorphism may modulate susceptibility to cancer by influencing the expression of survivin. A recent study has supported a role of survivin in colorectal carcinogenesis, while the −31 G/C polymorphism may constitute a marker of survival .
The angiotensin-converting enzyme (ACE), a major component of the renin-angiotensin system (RAS), plays a crucial role in the regulation of circulatory homeostasis such as blood pressure and serum electrolytes . It is located on human chromosome 17q23 and has been involved in the pathogenesis of human cancers [11,12]. Epidemiologic studies have indicated that inhibition of ACE activity could suppress tumor growth and angiogenesis, decreasing the risk and mortality rate . Recent research showed that long-term/high-dose exposure to ACE inhibitor may decrease the incidence of CRC . ACE variants might affect its activity. Among which, ACE I/D (rs4646994) polymorphism in intron 16 of this gene, based on insertion (I) or deletion (D) of a 287-bp Alu sequence, was the most widely studied and leaded to a change in the plasma ACE level. The carriers of D allele were shown in higher ACE activity.
Numerous studies have shown the association of these genetic polymorphisms with CRC [9,15-25]. However, the results remained inconsistent. In the present study, we performed meta-analyses to evaluate and summarize the contribution of the two polymorphisms to CRC susceptibility in different populations.
A comprehensive literature search was conducted using the online electronic database of Embase, Medline, PubMed, CNKI (China National Knowledge Infrastructure), and Wanfang. We retrieved the relevant articles published between January 2000 and March 2014 using the following terms: “colorectal cancer or colorectal carcinoma”, “angiotensin-converting enzyme or ACE”, “survivin”, and “polymorphism or variant or mutation” as well as their combinations. The references of retrieved articles were searched manually. When the same authors or laboratory reported the issue on the same group of people, only full-text articles of the most recent studies were included.
The inclusion criteria were as follows: 1) case–control or cohort studies, 2) evaluating the contribution of survivin −31 G/C and ACE I/D polymorphisms with CRC risk, 3) the results presented in odds ratio (OR) with its 95% confidence interval (CI), and 4) genotype distributions in the cases and controls were available to extract.
Two investigators independently assessed the data from the included studies. Any disagreement was discussed with a third expert to reach a final consensus. The following information was extracted: the name of first author, publication year, country, ethnicity, sample size, genotyping method, and the genotype frequencies in the cancer cases and controls.
The overall effect was measured by ORs with its 95% CI. The Z test was employed to determine the significance of the pooled ORs, and a P value less than 0.05 was considered statistically significant. The per-allele model (C vs. G for survivin, D vs. I for ACE), dominant model (GC + CC vs. GG for survivin, ID + DD vs. II for ACE), recessive model (CC vs. GC + GG survivin, DD vs. ID + II for ACE), and additive model (CC vs. GG for survivin, DD vs. II for ACE) were examined to assess these association. The I 2 test and the Q statistic test were used to assess the between-study heterogeneity. The Mantel-Haenszel (M-H) fixed-effects model is used when the P value is more than 0.10 for the Q test and less than 50% for I 2; otherwise, the random-effects model is used. The publication bias was assessed by visual funnel plot inspection. Review Manager (version 5.2, The Cochrane Collaboration) was used to conduct the statistical analyses. All the tests were two sided.
Study selection and characteristics
Main characteristic of the eligible studies
Survivin (−31 G/C)
Van der 
Liu SY 
Distribution of genotypes in the individual studies
Van derv 
Liu SY 
Association of survivin G/C polymorphism and CRC risk
Meta-analysis of survivin −31 G/C polymorphism in CRC by ethnicity analysis
OR (95% CI)
OR (95% CI)
OR (95% CI)
C vs. G
1.46 (1.33, 1.60)
1.42 (1.27, 1.58)
1.50 (1.07, 2.10)
CC vs. GG
1.95 (1.62, 2.35)
1.88 (1.52, 2.33)
1.78 (0.71, 4.45)
CC + GC vs. GG
1.51 (1.29, 1.76)
1.41 (1.17, 1.70)
1.75 (1.33, 2.31)
CC vs. GC + GG
1.72 (1.49, 1.99)
1.70 (1.44, 2.01)
1.37 (0.52, 3.62)
Association of ACE I/D polymorphism and CRC risk
Meta-analysis of ACE I/D polymorphism in CRC
OR (95% CI)
I 2 (%)
D vs. I
0.96 (0.84, 1.08)
DD vs. II
0.86 (0.66, 1.12)
DD + ID vs. II
0.97 (0.79, 1.19)
DD vs. ID + II
0.91 (0.74, 1.12)
Sensitivity analysis and publication bias
CRC is a major cause of morbidity and mortality worldwide. Although surgical resection remains a curative option for CRC treatment, most patients with CRC are not suited for surgical operations because of the advanced stage of the lesions when diagnosed. Thus, there is an urgent need to identify newer biomarkers to evaluate the severity of this disease, predict the prognosis of patients, and target the pathogenic genes.
Recently, survivin has been reported to be overexpressed in almost all human tumors. It is considered as a tumor-associated antigen for immune-based clinical approaches in CRC . Researchers have suggested that survivin is implicated in the progression of dysplasia to neoplasia in the colon . A significant role of survivin in CRC progression and recurrence of colon cancer liver metastases has been previously demonstrated . The mechanisms of the survivin re-expression in malignancies are still unclear due to the complexity of its regulation. Genetic variations located in the promoter of the survivin gene have impact on the protein expression and consequently contributed to the genetic susceptibility to cancers. The −31 G/C polymorphism is the most extensively studied variant located in the promoter region of survivin, and the C allele has been identified to be associated with a higher transcription activity of survivin . This meta-analysis showed that the survivin −31 G/C polymorphism was associated with increased CRC risk in total populations as well as in Asians, while no association was found in Caucasian except the dominant model. Our result is in agreement with the study conducted by Qin et al., which identified that this polymorphism is associated with elevated cancer risk .
Survivin acts as an antagonist of apoptotic cell death and functions as a regulator of mitosis [31,32]. It is a potentially interesting prognostic marker, implicating a shift from adenoma with low dysplasia to high dysplasia during human colorectal tumorigenesis . Survivin overexpression was related with the increase of invasion and the metastasis of CRC . A study conducted by Choi et al. suggested that the nuclear expression of survivin might be associated with the metastasis of CRC to the liver . Survivin can be regulated by or cooperated with other genes. The stimulation of survivin expression by TCF/β catenin might contribute to the molecular pathogenesis of CRC . The positive expression of survivin protein, directly correlated to that of Bcl-2, acted on different stages of apoptosis to promote jointly the development of CRC in a synergistic way . The combined expression levels of Aldh1, survivin, and EpCAM as strong independent prognostic factors for survival and tumor recurrence in colon cancer patients reflect tumor aggressiveness . Furthermore, survivin is also a therapeutic target in cancers . Survivin expression increases during the normal mucosa-adenoma-carcinoma sequence and is maintained throughout the progression of disease, which strengthens its appeal as a therapeutic target . The expression of survivin may play a role in identifying a subgroup of patients who could benefit from a targeted therapy against survivin in CRC .
Much evidence indicates that ACE associated with the pathology of carcinomas. It is differentially expressed in several malignancies. ACE is a monomeric glycoprotein that is distributed in many tissues and biological fluids . ACE can influence tumor cell migration, proliferation, metastatic behavior, and angiogenesis . The expression of ACE is upregulated in several cancers with functions of angiogenesis and tumor cell growth .
Previous meta-analysis showed that the ACE I/D polymorphism is associated with hepatocellular carcinoma (HCC), indicating that this polymorphism contributes to HCC progression in the Chinese population . Recent analysis suggested that the ACE I/D polymorphism might not be a common risk factor for overall cancer susceptibility . Our results did not show any association between ACE I/D polymorphism and CRC in each genetic models (P > 0.05). This is in accordance with meta-analysis conducted by Liu et al. and Zhang et al. [12,45].
Several limitations were presented in this meta-analysis. Firstly, the number of included studies in the subgroup analysis was small which may have a relatively lower power. Secondly, other covariates such as age, sex, and smoking condition should be considered if they are available in each individual study to obtain a more precise result. Thirdly, the gene-gene interaction which is important in developing complex diseases should also be included.
In conclusion, the results from the present meta-analysis suggest that the survivin −31 G/C polymorphism might be correlated with an increased risk of CRC, indicating it may serve as a biomarker of disease progression. However, ACE I/D polymorphism is not associated with CRC risk. Further large and well-designed studies in various populations are needed to confirm our results. Moreover, the studies of gene-gene and gene-environment interactions between these polymorphisms and CRC risk should also be performed and considered.
We thank Jinhai Wang in the Department of Colorectal Surgery, the First Affiliated Hospital, College of Medicine, Zhejiang University for the data analysis in this study.
- Wasserman M, Baxter N, Rosen B, Burnstein M, Halverson A. Systematic review of internet patient information on colorectal cancer surgery. Dis Colon Rectum. 2014;57(1):64–9.View ArticlePubMedGoogle Scholar
- Mäkinen MJ. Serrated polyps and colorectal cancer risk. Colorectal Cancer. 2014;3(1):77–91.View ArticleGoogle Scholar
- Siegel R, DeSantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):104–17.View ArticlePubMedGoogle Scholar
- Derks S, van Engeland M. Epigenetic disturbances in colorectal cancer. Epigenetic Therapy of Cancer. Springer; 2014. p. 283–98.Google Scholar
- Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011;6:479–507.View ArticlePubMedGoogle Scholar
- Srinivasula SM, Ashwell JD. IAPs: what’s in a name? Mol Cell. 2008;30(2):123–35.View ArticlePubMed CentralPubMedGoogle Scholar
- Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008;8(1):61–70.View ArticlePubMedGoogle Scholar
- Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3(8):917–21.View ArticlePubMedGoogle Scholar
- Antonacopoulou AG, Floratou K, Bravou V, Kottorou A, Dimitrakopoulos F-I, Marousi S, et al. The survivin-31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. Cell Oncol. 2011;34(4):381–91.View ArticleGoogle Scholar
- Krege JH, Kim H-S, Moyer JS, Jennette JC, Peng L, Hiller SK, et al. Angiotensin-converting enzyme gene mutations, blood pressures, and cardiovascular homeostasis. Hypertension. 1997;29(1):150–7.View ArticlePubMedGoogle Scholar
- Feng Y, Wan H, Liu J, Zhang R, Ma Q, Han B, et al. The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. Oncol Rep. 2010;23(4):941–8.PubMedGoogle Scholar
- Zhang Y, He J, Deng Y, Zhang J, Li X, Xiang Z, et al. The insertion/deletion (I/D) polymorphism in the angiotensin-converting enzyme gene and cancer risk: a meta-analysis. BMC Med Genet. 2011;12(1):159.View ArticlePubMed CentralPubMedGoogle Scholar
- Mc Menamin ÚC, Murray LJ, Cantwell MM, Hughes CM. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review. Cancer Causes Control. 2012;23(2):221–30.View ArticlePubMedGoogle Scholar
- Makar GA, Holmes JH, Yang Y-X. Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk. J Natl Cancer Inst. 2014;106(2):djt374.View ArticlePubMed CentralPubMedGoogle Scholar
- Sameer A, Nissar S, Bashir S, Bashir A, Siddiqi M. ACE polymorphism in colorectal cancer patients of Kashmiri population—a short report. Open Colorectal Canc J. 2011;4:1–5.View ArticleGoogle Scholar
- Gazouli M, Tzanakis N, Rallis G, Theodoropoulos G, Papaconstantinou I, Kostakis A, et al. Survivin −31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis. 2009;24(2):145–50.View ArticlePubMedGoogle Scholar
- Huang J, Wang J, Wang L, Liu H, Wei Y, Huang M, et al. Association between Survivin Promoter -31C/G Polymorphism and Genetic Susceptibility to Sporadic Colorectal Cancer. J SUN Yat-sen Univ (Med Sci). 2010;31(1):59–63 (in chinese).Google Scholar
- Duan F. The Study on the Relationship between Survivin promoter SNP and the Colorectal Cancer. Master's thesis. Lu Zhou medical college, 2012. (in chinese)Google Scholar
- Liu Y. The Association of Survivin Polymorphism with the Risk of Colorectal Cancer. Master's thesis. Hebei medical college, 2012. (in chinese)Google Scholar
- Li XB, Li SN, Yang ZH, Cao L, Duan FL, Sun XW. Polymorphisms of survivin and its protein expression are associated with colorectal cancer susceptibility in Chinese population. DNA Cell Biol. 2013;32(5):236–42.View ArticlePubMed CentralPubMedGoogle Scholar
- Nikiteas N, Tsigris C, Chatzitheofylaktou A, Yannopoulos A. No association with risk for colorectal cancer of the insertion/deletion polymorphism which affects levels of angiotensin-converting enzyme. In Vivo. 2007;21(6):1065–68.PubMedGoogle Scholar
- Rocken C, Neumann K, Carl-McGrath S, Lage H, Ebert MP, Dierkes J, et al. The gene polymorphism of the angiotensin I-converting enzyme correlates with tumor size and patient survival in colorectal cancer patients. Neoplasia. 2007;9(9):716–22.View ArticlePubMed CentralPubMedGoogle Scholar
- Van der Knaap R, Siemes C, Coebergh JW, Van Duijn CM, Hofman A, Stricker BH. Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study. Cancer. 2008;112(4):748–57.View ArticlePubMedGoogle Scholar
- Toma M, Cimponeriu D, Apostol P, Stavarachi M, Cojocaru M, Belusica L, et al. Lack of association between ACE ID polymorphism and colorectal cancer in Romanian patients. Chirurgia (Bucharest, Romania: 1990). 2008;104(5):553–56.Google Scholar
- Liu SY, Sima X, Wang CH, Gao M. The association between ACE polymorphism and risk of colorectal cancer in a Chinese population. Clin Biochem. 2011;44(14):1223–26.View ArticlePubMedGoogle Scholar
- Casati C, Dalerba P, Rivoltini L, Gallino G, Deho P, Rini F, et al. The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res. 2003;63(15):4507–15.PubMedGoogle Scholar
- Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer. 2001;91(11):2026–32.View ArticlePubMedGoogle Scholar
- Fan L-F, Dong W-G, Jiang C-Q, Qian Q, Yu Q-F. Role of hypoxia-inducible factor-1α and survivin in colorectal carcinoma progression. Int J Color Dis. 2008;23(11):1057–64.View ArticleGoogle Scholar
- Jang JS, Kim KM, Kang KH, Choi JE, Lee WK, Kim CH, et al. Polymorphisms in the < i > survivin </i > gene and the risk of lung cancer. Lung Cancer. 2008;60(1):31–9.View ArticlePubMedGoogle Scholar
- Qin Q, Zhang C, Zhu H, Yang X, Xu L, Liu J, et al. Association between survivin-31G > C polymorphism and cancer risk: meta-analysis of 29 studies. J Cancer Res Clin Oncol. 2014;140(2):179–88.View ArticlePubMedGoogle Scholar
- Skoufias DA, Mollinari C, Lacroix FB, Margolis RL. Human survivin is a kinetochore-associated passenger protein. J Cell Biol. 2000;151(7):1575–82.View ArticlePubMed CentralPubMedGoogle Scholar
- Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K, et al. An IAP-IAP complex inhibits apoptosis. J Biol Chem. 2004;279(33):34087–90.View ArticlePubMedGoogle Scholar
- Chu XY, Chen LB, Wang JH, Su QS, Yang JR, Lin Y, et al. Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer. J Surg Oncol. 2012;105(6):520–8.View ArticlePubMedGoogle Scholar
- Choi J, Chang H. The expression of MAGE and SSX, and correlation of COX2, VEGF, and survivin in colorectal cancer. Anticancer Res. 2012;32(2):559–64.PubMedGoogle Scholar
- Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC. Survivin and molecular pathogenesis of colorectal cancer. Lancet. 2003;362(9379):205–9.View ArticlePubMedGoogle Scholar
- Ma Y, Wang HS. Correlations of Bcl-2 and survivin gene protein expressions in colorectal cancer. Appl Mech Mater. 2013;423:362–5.View ArticleGoogle Scholar
- Goossens-Beumer I, Zeestraten E, Benard A, Christen T, Reimers M, Keijzer R, et al. Clinical prognostic value of combined analysis of Aldh1, survivin, and EpCAM expression in colorectal cancer. Br J Cancer. 2014;110(12):2935–44.View ArticlePubMedGoogle Scholar
- Mobahat M, Narendran A, Riabowol K. Survivin as a preferential target for cancer therapy. Int J Mol Sci. 2014;15(2):2494–516.View ArticlePubMed CentralPubMedGoogle Scholar
- Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen D-T, et al. Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer. 2011;10(3):188–93.View ArticlePubMedGoogle Scholar
- Krieg A, Werner TA, Verde PE, Stoecklein NH, Knoefel WT. Prognostic and clinicopathological significance of survivin in colorectal cancer: a meta-analysis. PLoS One. 2013;8(6):e65338.View ArticlePubMed CentralPubMedGoogle Scholar
- Guang C, Phillips RD, Jiang B, Milani F. Three key proteases–angiotensin-I-converting enzyme (ACE), ACE2 and renin—within and beyond the renin-angiotensin system. Arch Cardiovasc Dis. 2012;105(6):373–85.View ArticlePubMedGoogle Scholar
- Yates CJ, Masuyer G, Schwager SL, Akif M, Sturrock ED, Acharya KR. Molecular and thermodynamic mechanisms of the chloride-dependent human angiotensin-I-converting enzyme (ACE). J Biol Chem. 2014;289(3):1798–814.View ArticlePubMed CentralPubMedGoogle Scholar
- Xie Y, You C, Chen J. An updated meta-analysis on association between angiotensin I-converting enzyme gene insertion/deletion polymorphism and cancer risk. Tumor Biol. 2014;35(7):6567–79.View ArticleGoogle Scholar
- Yuan F, Zhang L-S, Li H-Y, Liao M, Lv M, Zhang C. Influence of angiotensin I-converting enzyme gene polymorphism on hepatocellular carcinoma risk in China. DNA Cell Biol. 2013;32(5):268–73.View ArticlePubMed CentralPubMedGoogle Scholar
- Liu J-F, Xie H-J, Cheng T-M. Lack of any association between insertion/deletion (I/D) polymorphisms in the angiotensin-converting enzyme gene and digestive system cancer risk: a meta-analysis. Asian Pac J Cancer Prev. 2013;14(12):7271–5.View ArticlePubMedGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.